FierceBiotech4h
Novartis inks $925M Anthos takeover to buy back phase 3 clot-busting candidate
Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...
Novartis4h
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...
M&A News: Novartis Seals $3.1B Deal to Acquire Anthos
Novartis (NVS) has sealed a $3.1 billion deal to acquire clinical-stage biopharmaceutical company Anthos Therapeutics. The ...
Novartis signs agreement to acquire Anthos for $925m upfront
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.OtgQHJex.js ...